Alison J. Moskowitz, MD
Medical Oncologist
Titles
Clinical Director, Lymphoma
Clinical Expertise
Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Cutaneous T Cell Lymphoma
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Moskowitz accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
- 646-608-3726 Office Phone
- Speaks English
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, Albert Einstein College of Medicine
Residencies
Internal Medicine - Columbia University Medical Center
Fellowships
Hematology/Medical Oncology - Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College
Board Certifications
Medical Oncology; Hematology
I am a hematologic oncologist who cares for people with lymphoma, including non-Hodgkin lymphoma. I have a particular focus on Hodgkin lymphoma, systemic T cell lymphoma, and cutaneous T cell lymphoma (a rare type of skin lymphoma).
Read more
I have been at Memorial Sloan Kettering for more than 11 years. I am part of a team of lymphoma experts who are committed not only to providing world-class care but also to finding newer and better ways to treat these diseases.
Hodgkin lymphoma is a relatively rare disease, but because of treatment advances, we can often cure it. By incorporating newer drugs into our current standard treatments, we can study how patients tolerate their treatment for Hodgkin lymphoma and can lessen the drugs’ long-term negative effects on the body.
T cell lymphoma is rare and can be challenging to treat. Our clinical trials in T cell lymphoma are testing targeted therapies and immunotherapies aimed at improving our ability to control the disease and patients’ quality of life — as well as the chance of a cure.
When I see patients for the first time, my goal is that they leave the appointment with a clear understanding of their diagnosis and treatment options, as well as the many resources available at MSK to help them cope with their treatment. I am fortunate to work with a team of nurses, social workers, and clinical assistants who create a comforting and supportive environment for our patients. While I understand that it is very scary for people to be told they have cancer, it is important to me that I help make the experience less scary and work with my patients so they feel as well as possible.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Moskowitz
- A Phase I Study of Nivolumab Immunotherapy plus Standard Chemotherapy for Newly Diagnosed High-Risk Hodgkin Lymphoma
- A Phase I Study of Ruxolitinib and Duvelisib to Treat Recurrent or Persistent T-Cell or NK-Cell Lymphomas
- A Phase II Study Assessing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- A Phase II Study of Pembrolizumab Immunotherapy plus Chemotherapy followed by Autologous Stem Cell Transplantation for Recurrent or Persistent Hodgkin Lymphoma
Read more
- A Phase II Study of Pembrolizumab Immunotherapy plus Gemcitabine to Treat Advanced Mycosis Fungoides or Sézary Syndrome
- A Phase II Study of Pembrolizumab Immunotherapy plus Involved Site Radiation Therapy to Treat Early Recurrent or Persistent Hodgkin Lymphoma
- A Phase II Study of Ruxolitinib in Patients with Persistent or Recurrent T-Cell or NK-Cell Lymphoma
- A Pilot Study of Pembrolizumab Immunotherapy in Patients with Extranodal NK/T-cell Nasal-Type Lymphoma
- Clinical Trials Co-Investigated by Dr. Moskowitz
- A Phase I Study Assessing the Addition of Lenalidomide to the Usual Combination Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma
- A Phase I Study of DS-3201b in People with Recurrent or Persistent Lymphoma
- A Phase I Study of TTI-621 Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
- A Phase II Study of AFM13 in People with T-Cell Lymphoma that Has Not Responded to Treatment
- A Phase II Study of Brentuximab Vedotin and CHP Chemotherapy in People with Previously Untreated Peripheral T-Cell Lymphoma
- A Phase II Study of CD30-Directed CAR T-Cell Therapy in People with Hodgkin Lymphoma
- A Phase II Study of Duvelisib in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma
- A Phase II Study of Entinostat plus Pembrolizumab Immunotherapy for Recurrent or Persistent Hodgkin Lymphoma
- A Phase II Study of Valemetostat Tosylate in People with Persistent Peripheral T-Cell Lymphoma or Adult T-Cell Leukemia/Lymphoma
- A Phase II Study to Determine the Optimal Dose of Brentuximab Vedotin for Mycosis Fungoides and Lymphomatoid Papulosis
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Moskowitz’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedDisclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Alison J. Moskowitz discloses the following relationships and financial interests:
-
Imbrium Therapeutics L.P.
Provision of Services -
Janpix Limited
Provision of Services -
Merck Sharp & Dohme
Provision of Services -
Physicians' Education Resource
Provision of Services
-
Seattle Genetics
Provision of Services -
Takeda Pharmaceuticals
Provision of Services -
WebMD
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.